Lack of clinical efficacy of a phosphodiesterase-4 inhibitor for treatment of heaves in horses.
Authors: Lavoie Jean-Pierre, Pasloske Kirby, Joubert Philippe, Cordeau Marie-Eve, Mancini Joseph, Girard Yves, Friesen Richard W, Frenette Richard, Blouin Marc, Young Robert N, Hickey Gerry
Journal: Journal of veterinary internal medicine
Summary
# Heaves Treatment: PDE-4 Inhibitors Fall Short in Clinical Trial Phosphodiesterase-4 inhibitors have demonstrated anti-inflammatory potential across various disease models, yet their effectiveness in equine recurrent airway obstruction (RAO or "heaves") remained unexplored until this investigation. Two separate trials assessed L-826,141—first in a randomised, blinded design comparing the drug to dexamethasone and placebo in heaves-affected horses exposed to moldy hay, and second in an open study examining higher dosing protocols over eight days. Despite achieving 90% suppression of TNF-alpha and leukotriene B4 production in ex vivo blood assays following repeated administration, L-826,141 produced no measurable improvement in pulmonary function or airway mechanics, whereas dexamethasone significantly improved lung function across all treated horses and showed no adverse effects on bronchoalveolar lavage (BAL) cytology. The failure of a pharmacologically active compound to translate in vivo efficacy suggests that PDE-4 inhibition may not address the primary inflammatory pathways driving heaves pathophysiology. For practitioners, this work reinforces that in vitro anti-inflammatory activity cannot predict clinical benefit in RAO, and corticosteroids remain the evidence-backed approach for managing acute airway obstruction—whilst researchers must continue investigating alternative inflammatory mediators and therapeutic targets more directly implicated in heaves pathogenesis.
Read the full abstract on PubMed
Practical Takeaways
- •PDE-4 inhibitors are not effective treatments for heaves despite showing promise in other inflammatory conditions, so do not expect clinical benefit from this drug class
- •Corticosteroids (dexamethasone) remain the proven pharmacological approach for improving airway function in heaves cases
- •The disconnect between in vitro anti-inflammatory effects and clinical outcomes emphasizes the importance of in vivo efficacy testing before adopting new therapeutic approaches
Key Findings
- •L-826,141 inhibited ex vivo TNF-alpha and LTB4 production by up to 90% but failed to improve lung function in horses with heaves
- •Dexamethasone significantly improved lung mechanics and airway function in all treated horses, while L-826,141 showed no improvement
- •Neither L-826,141 nor dexamethasone had significant effects on bronchoalveolar lavage total cell counts or differential cytology
- •PDE-4 enzyme inhibition does not appear to be a key mediator of lung inflammation in equine heaves despite documented anti-inflammatory activity